https://www.selleckchem.com/products/gw788388.html
001). By landmark analysis, differences between the two devices emerged after the first year and were maintained thereafter. The individual endpoints of mortality (HR [95%CI] = 0.70 [0.58-0.84], p less then 0.01), MI (HR [95%CI] = 0.55 [0.42-0.74], p less then 0.001), and repeat PCI (HR [95%CI] = 0.65 [0.53-0.73], p less then 0.001) were all significantly lower in the EES-treated patients. Stroke risk did not differ between EES and R-ZES. In ACS, a greater long-term clinical efficacy with EES vs. R-ZES was observed. This difference bec
Like
Comment
Share
